Sign In
Buy KVUE
$16.83
-0.490 (-2.83%)
At Close: Jun 03, 2026
Renaissance Capital Bets Big on Tylenol and Kenvue (KVUE) By Purchasing Over 351,000 Shares
11:46am, Monday, 27'th Oct 2025
Renaissance Capital bought 351,259 additional shares of Kenvue; estimated trade value of approximately $7.17 million, based on the average price in Q3 2025 This trade represented 4.02% of Renaissance
Time To Buy The Dip In Kenvue Stock?
10:25am, Monday, 27'th Oct 2025
Kenvue (NYSE:KVUE), the consumer healthcare spin-off from Johnson & Johnson, has experienced a significant decline in its stock price in recent months. The shares are currently priced around $15, whic
Kenvue to Announce Third Quarter 2025 Results on November 6, 2025
06:45am, Monday, 27'th Oct 2025
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its third quarter 2025 financial results before the market opens on November 6, 2025. The company will host a conference call and
3 Healthcare Stocks Paying the Highest Dividends of 2025
04:30am, Monday, 27'th Oct 2025
Kenvue was spun off from Johnson & Johnson in mid-2023, and its life is starting out a little rough. Pfizer is working through typical drug industry issues, but there's a notable dividend risk to cons
Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever.
04:00am, Sunday, 26'th Oct 2025
Kenvue owns Johnson & Johnson's former over-the-counter brands. Medtronic has a diversified medical-device portfolio and is closing in on "Dividend King" status.
US IPO Weekly Recap: 5 Small IPOs Debut, As Government Shutdown Drags On
05:43am, Saturday, 25'th Oct 2025
Five small IPOs debuted and four SPACs listed this week as the government shutdown continues to complicate listings. Two sizable IPOs are scheduled for the week ahead, both of which launched after the
Starboard Value CEO: We're thrilled to own Kenvue at this valuation
11:07am, Tuesday, 21'st Oct 2025
Starboard Value CEO Jeff Smith joins CNBC's David Faber from 13D Monitor's Active-Passive Investor Summit.
Kenvue urges US FDA to deny request for Tylenol's autism warning
12:35pm, Monday, 20'th Oct 2025
Kenvue has urged U.S. regulators to reject a request for a warning of autism on its popular over-the-counter pain medication Tylenol for use during pregnancy, according to a petition.
Meet the 5%-Yielding Dividend Stock That Could Soar in 2026
01:25pm, Sunday, 19'th Oct 2025
Kenvue (KVUE 8.43%) isn't a household name. The consumer health products company has been around in its current form for only a couple of years.
What Moved Markets This Week
07:17am, Saturday, 18'th Oct 2025
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
September Readers ID'd 17 Ideal 'Safer' Dividends In 39 Dogs
05:54pm, Friday, 17'th Oct 2025
This article highlights top ReFa/Ro dividend stocks for September 2025, focusing on high yield and analyst-projected returns through September 2026. MFA Financial, Hafnia, and Energy Transfer lead the
Top Stock Movers Now: Oracle, Newmont, Kenvue, American Express, and More
01:20pm, Friday, 17'th Oct 2025
Major U.S. equities indexes climbed at midday Friday as regional bank stocks rebounded from yesterday's losses after a flurry of corporate earnings reports. The Dow, S&P 500, and Nasdaq were all highe
Why Kenvue Stock Tumbled by 13% on Thursday
06:06pm, Thursday, 16'th Oct 2025
A potential legal headache for consumer healthcare giant Kenvue (KVUE -13.50%) was causing pain for investors on Thursday. Such troubles tend to spook the market; hence the more than 13% sell-off of K
S&P 500 Gains and Losses Today: Regional Banks Slump on Worries About Bad Loans; Data Storage Stocks Surge
05:45pm, Thursday, 16'th Oct 2025
Reports of elevated loan losses from regional banks weighed on the sector, while expectations of AI-driven growth helped lift shares of companies in the data storage and memory chip businesses.
Kenvue: A Rock Solid 5% Yield
08:45am, Wednesday, 15'th Oct 2025
Kenvue offers stable financials, a robust 5% dividend yield, and the stock trades at a significant discount to peers and historical averages. KVUE's recent decline, driven by Tylenol-related headlines
